Form 4: Revolution Medicines' General Counsel Sells Shares to Cover Tax Obligations

Jeff Cislini, General Counsel of Revolution Medicines, sold 1,757 shares of common stock on June 17, 2024, to cover tax obligations related to vesting restricted stock units.

Summary

• On June 17, 2024, Jeff Cislini, the General Counsel of Revolution Medicines, sold 1,757 shares of the company's common stock.
• The sale was executed at a weighted average price of $37.3874 per share.
• This transaction was made to satisfy the reporting person's tax withholding obligation upon the vesting of restricted stock units (RSUs).
• The sale was conducted under a Rule 10b5-1 trading plan adopted on May 31, 2023.
• Following the transaction, Cislini beneficially owns 51,487 shares, including 44,217 RSUs and 370 shares acquired under the Employee Stock Purchase Plan on May 31, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a routine transaction for tax purposes and doesn't indicate any fundamental change in the company's prospects or insider confidence.

Industry Context

Sales of shares by company insiders are a normal part of corporate governance, especially when related to tax obligations from vesting equity. These sales are often pre-planned under Rule 10b5-1 to avoid accusations of insider trading.

Comparison to Industry Standards

• Similar sales by executives at comparable biotech companies like Amgen, Gilead, and Vertex are common for managing personal finances and tax liabilities.
• Rule 10b5-1 plans are a standard practice among public company executives to ensure compliance with insider trading regulations.

Stakeholder Impact

• The sale is unlikely to have a significant impact on shareholders, as it is a small percentage of the total outstanding shares and was pre-planned.

Key Dates